John Johnson Biography and Net Worth

Director of Xeris Biopharma

John H. Johnson is a recognized leader in the biopharmaceutical industry with more than three decades of experience. He currently serves as the Chief Executive Officer if Reaction Biology, a biotechnology company. Prior to Reaction Biology, he was the CEO of Strongbridge Biopharma plc prior to its acquisition by Xeris Biopharma Holdings. Mr. Johnson has held executive management roles at leading global corporations, including Johnson & Johnson, where he spent the majority of career. He served as the Company Group Chairman of Biopharmaceuticals within Johnson & Johnson, where he was responsible for the Johnson & Johnson Biotechnology, Immunology and Oncology commercial businesses. Mr. Johnson also served as President of Eli Lilly & Company’s Worldwide Oncology Unit, following the company’s 2008 acquisition of ImClone Systems, Inc., where he served as CEO and a member of ImClone’s Board of Directors. John is also an experienced Director having served on numerous boards across industry, biotech, and biopharmaceutical services companies. Mr. Johnson serves on the Boards of Axogen (AXGN), and Verastem Oncology (VSTM).

Mr. Johnson holds a BS from East Stroudsburg University of Pennsylvania.

What is John Johnson's net worth?: The estimated net worth of John Johnson is at least $5.14 million as of December 19th, 2025. Johnson owns 698,083 shares of Xeris Biopharma stock worth more than $5,137,891 as of February 3rd. This net worth estimate does not reflect any other assets that Johnson may own. Additionally, Johnson receives a salary of $596,970.00 as Director at Xeris Biopharma. Learn More about John Johnson's net worth.
How old is John Johnson?: Johnson is currently 61 years old. There are 4 older executives and no younger executives at Xeris Biopharma. The oldest executive at Xeris Biopharma is Mr. Paul R. Edick, Chairman & CEO, who is 68 years old. Learn More on John Johnson's age.
What is John Johnson's salary?: As the Director of Xeris Biopharma Holdings, Inc., Johnson earns $596,970.00 per year. There are 4 executives that earn more than Johnson. The highest earning executive at Xeris Biopharma is Mr. Paul R. Edick, Chairman & CEO, who commands a salary of $1,210,000.00 per year. Learn More on John Johnson's salary.
How do I contact John Johnson?: The corporate mailing address for Johnson and other Xeris Biopharma executives is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. Xeris Biopharma can also be reached via phone at (844) 445-5704 and via email at [email protected]. Learn More on John Johnson's contact information.
Has John Johnson been buying or selling shares of Xeris Biopharma?: John Johnson has not been actively trading shares of Xeris Biopharma in the last ninety days. Most recently, John Johnson sold 135,400 shares of the business's stock in a transaction on Friday, December 19th. The shares were sold at an average price of $7.22, for a transaction totalling $977,588.00. Following the completion of the sale, the director now directly owns 698,083 shares of the company's stock, valued at $5,040,159.26. Learn More on John Johnson's trading history.
Who are Xeris Biopharma's active insiders?: Xeris Biopharma's insider roster includes Paul Edick (Insider), Dawn Halkuff (Director), Beth Hecht (Insider), John Johnson (Director), Kevin McCulloch (President and Chief Operating Officer), Marla Persky (Director), John Shannon, Jr. (Insider), and Jeffrey Sherman (Director). Learn More on Xeris Biopharma's active insiders.
Are insiders buying or selling shares of Xeris Biopharma?: In the last year, Xeris Biopharma insiders bought shares 1 times. They purchased a total of 25,000 shares worth more than $109,500.00. In the last year, insiders at the sold shares 14 times. They sold a total of 527,949 shares worth more than $3,809,478.75. The most recent insider tranaction occured on February, 2nd when insider Beth Hecht sold 16,667 shares worth more than $124,169.15. Insiders at Xeris Biopharma own 4.6% of the company. Learn More about insider trades at Xeris Biopharma.
Information on this page was last updated on 2/2/2026.

John Johnson Insider Trading History at Xeris Biopharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/19/2025	Sell	135,400	$7.22	$977,588.00	698,083
8/13/2025	Sell	107,500	$7.32	$786,900.00	833,483

John Johnson Buying and Selling Activity at Xeris Biopharma

Xeris Biopharma Company Overview

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Today's Range

Now: $7.40

$7.30

$7.56

50 Day Range

MA: $7.28

$6.47

$8.13

2 Week Range

Now: $7.40

$3.44

$10.08

Volume

179,736 shs

Average Volume

2,031,336 shs

Market Capitalization

$1.23 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52

John Johnson Biography and Net Worth

What is John Johnson's net worth?

How old is John Johnson?

What is John Johnson's salary?

How do I contact John Johnson?

Has John Johnson been buying or selling shares of Xeris Biopharma?

Who are Xeris Biopharma's active insiders?

Are insiders buying or selling shares of Xeris Biopharma?